Structure-Guided Glycosylation of Hemagglutinin Enhances Stability and Modulates Immunogenicity of Influenza Vaccines
Vaccines · 15.05.2026 · 14 (5) · 443
DOI: 10.3390/vaccines14050443 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 15.05.2026. Verfasst von Zheng Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Antigenic drift limits the protective efficacy of influenza vaccine. Glycosylation of hemagglutinin (HA) represents a promising immunofocusing strategy that enhances neutralizing antibody responses by masking immunodominant non-neutralizing epitopes.
Methods
B-cell epitopes of influenza viruses were retrieved from the Immune Epitope Database and were mapped onto the HA structure of A/Puerto Rico/8/1934 (H1N1). Structure-guided analysis identified residues 136 and 137 as candidate sites for N-linked glycosylation (NLG). Single-site mutants (136NLG and 137NLG) were generated using reverse genetics and evaluated for stability, receptor binding, viral replication, and immunogenicity in a murine model with inactivated whole-virus vaccines.
Results
Both mutants exhibited increased thermostability at 42 °C. Glycosylation reduced the HA–sialic acid affinity, resulting in decreased viral adsorption and internalization efficiency in MDCK cells, and delayed viral replication at low multiplicity of infection (MOI). In vivo, all vaccine groups provided complete protection against lethal challenge; notably, the 136NLG group exhibited reduced weight loss, indicating improved protective efficacy compared with wild-type (WT).
Conclusions
Targeted glycosylation at residue 136 in the HA head domain effectively enhances the viral stability and elicits a 1.78-fold increase in hemagglutination inhibition titer (GMT) relative to the WT, thereby improving vaccine performance. These findings establish a rational and structure-based design strategy for developing more stable and effective influenza vaccines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China.
- Shanghai Collaborative Innovation Center for Biomanufacturing Technology (SCIBT), Shanghai 200237, China.
- Department of Virology & Vaccine, Shanghai Institute of Biological Products, Shanghai 200052, China.
- Shanghai BioEngine Sci-Tech Co., Ltd., Shanghai 201203, China.
ORCID-Profile: Qian Ye, Wen-Song Tan
Zitieren
APA
Zhang, Z., Xiao, Z., Zhang, X., Ye, Q., Zhang, X., & Tan, W. S. (2026). Structure-Guided Glycosylation of Hemagglutinin Enhances Stability and Modulates Immunogenicity of Influenza Vaccines. Vaccines, 14(5), 443. https://doi.org/10.3390/vaccines14050443
Vancouver
Zhang Z, Xiao Z, Zhang X, Ye Q, Zhang X, Tan WS. Structure-Guided Glycosylation of Hemagglutinin Enhances Stability and Modulates Immunogenicity of Influenza Vaccines. Vaccines. 2026;14(5):443. doi:10.3390/vaccines14050443
BibTeX
@article{Zhang2026,
author = {Zhang, Zheng and Xiao, Zhiying and Zhang, Xu and Ye, Qian and Zhang, Xin and Tan, Wen-Song},
title = {Structure-Guided Glycosylation of Hemagglutinin Enhances Stability and Modulates Immunogenicity of Influenza Vaccines},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {5},
pages = {443},
doi = {10.3390/vaccines14050443}
}
EUVIMED